Roswell Park Appoints Cell Therapy Specialist as Senior Vice President

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Marco DavilaMD, PhD, was named Senior Vice President and Associate Director for Translational Research at Roswell Park Comprehensive Cancer Center.

Davila will also serve as vice president for cell therapies.

“What excites me most about joining Roswell Park is that they have already invested significant resources to be a site that can support clinical investigation of local and industry-sponsored cell therapies,” said Davila in a press release. “I’m really excited to have this opportunity to work with the cell therapy teams, as well as Roswell Park management, to take advantage of these facilities and staff to advance our gene and cell therapies and also to work with biotechnologies, startups [and] pharmaceutical companies to bring these exciting therapies to patients in Roswell Park.

Davila Marco

Marco Davila

Davila was previously a senior member of the blood and bone marrow transplant department and director of the cell therapy facility at Moffitt Cancer Center.

When Davila was completing his residency and fellowship at Memorial Sloan Kettering Cancer Center, he served as a clinical investigator on the Renier Brentjens, MD, PhD.

Davila worked with Brentjens — now deputy director of Roswell Park — to develop some of the first chimeric antigen receptor T-cell therapies to treat patients with hematological malignancies.

“Dr. Davila is a gifted physician and an accomplished translational scientist,” Brentjens said in the statement. “He is very attuned to the needs and priorities of his patients, but also capable of great scientific imagination when it considers new treatment strategies and designs the studies to develop them.”

Comments are closed.